Want to see JSPR full AI Analyst Report?
JSPR Stock Chart & Stats
$0.69
-$0.03(-3.63%)
At close: 4:00 PM EDT
$0.69
-$0.03(-3.63%)
Day’s Range― - ―
52-Week Range$0.32 - $3.14
Previous CloseN/A
Volume381.42K
Average Volume (3M)399.98K
Market Cap
$17.69M
Enterprise Value$11.74
Total Cash (Recent Filing)$14.14M
Total Debt (Recent Filing)$757.00K
Price to Earnings (P/E)―
Beta2.81
Next Earnings
Aug 07, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.40
Shares Outstanding28,079,552
10 Day Avg. Volume455,991
30 Day Avg. Volume399,984
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)8.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.45
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.00Price Target Upside334.78% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.74
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Extended Cash Runway (PIPE)The $132M PIPE materially extends operating runway into at least the second half of 2028, reducing near-term financing pressure. That durable funding supports multi-phase clinical programs and milestone-driven development, lowering execution risk and enabling planned trials and regulatory interactions.
Expanded Pipeline Via Kira AcquisitionAcquiring Kira adds complementary biologic programs, diversifying asset risk beyond a single lead antibody. The expanded pipeline plus out-licensing of non-core assets creates multiple development pathways and potential value catalysts, strengthening long-term strategic optionality and portfolio resilience.
Low Absolute LeverageVery low debt reduces refinancing and interest coverage pressure, preserving flexibility while the company burns cash. In a capital-intensive biotech model, limited leverage provides structural downside protection and fewer creditor constraints on strategic choices during clinical development.
Bears Say
Pre-revenue With High Cash BurnSustained pre-revenue status and recurring ~-$46M annual operating cash burn mean the business depends on external capital to advance trials. Persistent cash outflows increase dilution risk, constrain discretionary R&D, and make program timelines vulnerable to funding cycles or clinical setbacks over the next 2–6 months.
Sharply Reduced Equity CushionA collapsed equity base leaves little internal capital buffer and heightens sensitivity to new financings. That structural erosion of shareholder capital raises the likelihood of further dilutive transactions or strategic alternatives, limiting long-term financing flexibility and increasing investor dilution risk.
Listing Compliance & Strategic UncertaintyA Nasdaq non-compliance notice creates the potential need for corporate actions (reverse split, restructuring) that are disruptive and signal governance/marketability risk. Coupled with an open strategic-alternatives review, this raises durable execution uncertainty and could deter longer-horizon institutional support.
Jasper Therapeutics News
JSPR FAQ
What was Jasper Therapeutics’s price range in the past 12 months?
Jasper Therapeutics lowest stock price was $0.32 and its highest was $3.14 in the past 12 months.
What is Jasper Therapeutics’s market cap?
Jasper Therapeutics’s market cap is $17.69M.
When is Jasper Therapeutics’s upcoming earnings report date?
Jasper Therapeutics’s upcoming earnings report date is Aug 07, 2026 which is in 5 days.
How were Jasper Therapeutics’s earnings last quarter?
Jasper Therapeutics released its earnings results on May 14, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.486 by $0.446.
Is Jasper Therapeutics overvalued?
According to Wall Street analysts Jasper Therapeutics’s price is currently Undervalued.
Does Jasper Therapeutics pay dividends?
Jasper Therapeutics does not currently pay dividends.
What is Jasper Therapeutics’s EPS estimate?
Jasper Therapeutics’s EPS estimate is -0.25.
How many shares outstanding does Jasper Therapeutics have?
Jasper Therapeutics has 28,079,552 shares outstanding.
What happened to Jasper Therapeutics’s price movement after its last earnings report?
Jasper Therapeutics reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.486. Following the earnings report the stock price went down -11.366%.
Which hedge fund is a major shareholder of Jasper Therapeutics?
Currently, no hedge funds are holding shares in JSPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Jasper Therapeutics
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
JSPR Stock 12 Month Forecast
Average Price Target
$3.00
▲(334.78% Upside)
Technical Analysis
Ownership Overview
1.15% Insiders
5.11% Mutual Funds
33.37% Other Institutional Investors
56.30% Public Companies and
Individual Investors